Recently, activation of GLIPR1 with an adenoviral clinical vector, in association with radiotherapy, significantly suppressed tumor growth and extended survival in prostate and bladder cancer in vivo models, suggesting that GLIPR1 activation should be explored as a potential therapeutic strategy at least in prostate and bladder tumors [52]. This evidence concerns the gene GLIPR1 and urinary bladder cancer.